NEUROENDOCRINE NEOPLASMS
Clinical trials for NEUROENDOCRINE NEOPLASMS explained in plain language.
Never miss a new study
Get alerted when new NEUROENDOCRINE NEOPLASMS trials appear
Sign up with your email to follow new studies for NEUROENDOCRINE NEOPLASMS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Promising radioactive therapy targets rare tumors in new trial
Disease control Recruiting nowThis study tests a radioactive drug called Lu-177-DOTATATE in people with rare tumors (pheochromocytoma or paraganglioma) that cannot be surgically removed. The goal is to see if the drug can slow or stop tumor growth and to check its safety. Participants receive four doses about…
Matched conditions: NEUROENDOCRINE NEOPLASMS
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 00:51 UTC
-
New drug combo aims to shrink Hard-to-Treat gut tumors
Disease control Recruiting nowThis study tests whether combining Lutathera (a radioactive drug) with Olaparib (a targeted pill) can shrink neuroendocrine tumors in the pancreas or intestine that cannot be removed by surgery. About 56 adults will receive the treatment over several months and be monitored for s…
Matched conditions: NEUROENDOCRINE NEOPLASMS
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 00:51 UTC
-
New combo therapy targets tough-to-treat neuroendocrine cancers
Disease control Recruiting nowThis early-phase study tests a new drug called BI 764532 given together with standard chemotherapy for people with advanced neuroendocrine carcinoma (NEC). The goal is to find safe doses and see if the combination helps shrink tumors. About 55 adults whose cancers have a specific…
Matched conditions: NEUROENDOCRINE NEOPLASMS
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New hope for rare cancer: Real-World drug study launches
Disease control Recruiting nowThis study is testing a drug called surufatinib in 350 adults with advanced neuroendocrine tumors, a rare type of cancer. The goal is to see how well the drug controls the disease and what side effects occur when used in regular medical practice. Participants take the drug daily …
Matched conditions: NEUROENDOCRINE NEOPLASMS
Phase: PHASE4 • Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated May 11, 2026 20:48 UTC
-
New immune therapy shows promise for Tough-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug, BI 764532 (obrixtamig), in adults with advanced small cell lung cancer or other neuroendocrine cancers that have stopped responding to treatment. The drug is designed to help the immune system attack cancer cells. The main goals are to find a safe dos…
Matched conditions: NEUROENDOCRINE NEOPLASMS
Phase: PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated May 05, 2026 11:55 UTC
-
New imaging study tracks cancer Drug's path in Hard-to-Treat tumors
Knowledge-focused Recruiting nowThis study looks at how the medicine BI 764532 moves through the body and reaches tumors in people with advanced small cell lung cancer or other neuroendocrine cancers. It involves 12 adults who have not responded to other treatments. Doctors use PET scans to track the medicine a…
Matched conditions: NEUROENDOCRINE NEOPLASMS
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Knowledge-focused
Last updated May 13, 2026 16:02 UTC